MetaVia’s (MTVA) “Buy” Rating Reaffirmed at HC Wainwright

MetaVia (NASDAQ:MTVA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. Wall Street Zen raised MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average price target of $26.50.

MetaVia Stock Performance

MTVA stock remained flat at $1.11 during mid-day trading on Monday. 13,404 shares of the company’s stock were exchanged, compared to its average volume of 215,152. MetaVia has a 52 week low of $0.97 and a 52 week high of $19.03. The stock has a 50-day moving average of $1.39 and a two-hundred day moving average of $4.51. The stock has a market capitalization of $5.73 million, a P/E ratio of -0.13 and a beta of 0.59.

MetaVia (NASDAQ:MTVA) last issued its earnings results on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Research analysts forecast that MetaVia will post -2.72 earnings per share for the current year.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. Institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.